The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.
Read More
Emmis Corp. CEO Jeff Smulyan says he believes his fourth pitch to take the Indianapolis-based media company private will be successful.
Read More
Eli Lilly and Co. shares have soared 57% over the past 52 weeks, buoyed in part by sales of its diabetes drug Mounjaro, which the company is also preparing to seek approval to market for obesity.
Read More
The Greenfield-based maker of animal medicines said fourth-quarter revenue fell due to “environmental and competitive pressure” and could continue to slip this year.
Read More
Trump’s victory and the possibility of a Republican sweep of government buoyed investor hopes that his reelection could usher in an era of loosened government regulation and lower taxes, analysts said.
The Indianapolis-based health insurance giant said Thursday that its Medicaid enrollment tumbled 19% from 11 million people in last year’s third quarter.
Treasury yields also climbed in the bond market in a signal investors are feeling less worried about the economy after a report showed fewer U.S. workers applied for unemployment benefits last week.
Stronger-than-expected profit reports from several big U.S. companies helped drive the market.
U.S. stock markets plummeted Monday, with two major indexes racking up their worst day of trading in almost two years.
Nearly everything on Wall Street is tumbling Monday as fear about a slowing U.S. economy worsens and sets off another sell-off for financial markets around the world.
Several online brokerage firms appeared to be down for thousands of users early Monday during one of the biggest stock markets sell-offs of 2024.
A report Friday showing hiring by U.S. employers slowed last month by much more than expected has convulsed financial markets, vanquishing the euphoria that had taken the Nikkei 225 to all-times highs of over 42,000 in recent weeks.
Worries are rising the Federal Reserve might have kept its main interest rate at a two-decade high for too long.
The spotlight is turning to Indianapolis-based Eli Lilly and Co. as the next possible member of the so-called “Trillion-Dollar Club,” based on the drugmaker’s climbing stock price and swelling demand for its treatments for diabetes, obesity and other diseases.
Unlike other record-setting days, Tuesday’s came after a widespread rally where nearly nine out of every 10 stocks in the S&P 500 rose, instead of just the handful of influential Big Tech stocks.
Early last week, Nvidia overtook Microsoft as Wall Street’s most valuable public company. Then it fell 13% over three days, its worst such stretch since 2022.
The company’s journey to be one of the most prominent players in AI has produced some eye-popping numbers. Here’s a look:
Stocks have continued to hold up despite the worst inflation in decades, the punishing effects of high interest rates and worries about a recession that seemed inevitable but hasn’t arrived.
More worries about inflation and interest rates staying high knocked U.S. stocks lower on Tuesday, as the market closed out its worst month since September.
Before trading began, Trump Media had a market value of about $6.8 billion, a figure that will rise significantly if the early gains in the shares hold.
The financial markets cheered the message Wednesday from Jerome Powell and the Federal Reserve, with traders sending the Dow Jones industrial average surging 1%, to another all-time high.
In the past 52 weeks, shares have set new records almost every week, due to investor eagerness over the company’s new drugs for obesity and diabetes, two health conditions that plague America, along with other drugs in the pipeline.
Ancora Holdings Group LLC said the animal health company has underperformed its peers and destroyed billions of dollars of shareholder value.
Shares in the Indianapolis-based drugmaker are setting new records almost every day, due to investor excitement over the company’s new drugs for obesity and diabetes, two health conditions that plague America.
